Biotech developing autologous stem cell therapies for neurological disorders.
| Date | Round | Amount |
|---|---|---|
| Nov 2021 | Series B Maastricht biotech Neuroplast raised a EUR 10M Series B from Lumana Invest, Brightlands Venture Partners and others to advance its spinal cord injury therapy. | $11.8M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.